ALK-Abelló Valuation

Q: What is the Fair Price of ALK B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ALK B (DKK144.1) is trading below our estimate of [[fair value]] (DKK213.29)

Is ALK B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALK B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

DKK 213.29

Fair Value

32.4% undervalued

Number of Analysts

Below Fair Value: ALK B (DKK144.1) is trading below our estimate of fair value (DKK213.29)

Significantly Below Fair Value: ALK B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALK B?

Key metric: As ALK B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALK B. This is calculated by dividing ALK B's market cap by their current earnings.
What is ALK B's PE Ratio?
PE Ratio	39.1x
Earnings	DKK 815.00m
Market Cap	DKK 32.87b

ALK B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6x
Enterprise Value/EBITDA	26.1x
PEG Ratio	2.5x

Price to Earnings Ratio vs Peers

How does ALK B's PE Ratio compare to its peers?

The above table shows the PE ratio for ALK B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	21.3x
HLUN B H. Lundbeck	8.7x	6.3%	DKK 26.5b
NOVO B Novo Nordisk	17.1x	13.3%	DKK 1.9t
GMAB Genmab	10.4x	13.6%	DKK 80.8b
CHEMM ChemoMetec	49.1x	17.7%	DKK 8.3b
ALK B ALK-Abelló	39.1x	15.5%	DKK 31.9b

Price-To-Earnings vs Peers: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the peer average (21.3x).

Price to Earnings Ratio vs Industry

How does ALK B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the European Pharmaceuticals industry average (20.9x).

Price to Earnings Ratio vs Fair Ratio

What is ALK B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALK B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	39.1x
Fair PE Ratio	19.5x

Price-To-Earnings vs Fair Ratio: ALK B is expensive based on its Price-To-Earnings Ratio (39.1x) compared to the estimated Fair Price-To-Earnings Ratio (19.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALK B forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	DKK 144.10	DKK 181.25 +25.8%	3.7%	DKK 190.00	DKK 173.00	n/a	4
Apr ’26	DKK 141.00	DKK 181.25 +28.5%	3.7%	DKK 190.00	DKK 173.00	n/a	4
Mar ’26	DKK 153.10	DKK 181.25 +18.4%	3.7%	DKK 190.00	DKK 173.00	n/a	4
Feb ’26	DKK 162.80	DKK 180.75 +11.0%	3.9%	DKK 190.00	DKK 173.00	n/a	4
Jan ’26	DKK 159.10	DKK 172.75 +8.6%	7.6%	DKK 190.00	DKK 153.00	n/a	4
Dec ’25	DKK 162.00	DKK 181.20 +11.9%	11.4%	DKK 215.00	DKK 153.00	n/a	5
Nov ’25	DKK 163.60	DKK 177.00 +8.2%	9.3%	DKK 200.00	DKK 153.00	n/a	5
Oct ’25	DKK 171.10	DKK 177.00 +3.4%	9.3%	DKK 200.00	DKK 153.00	n/a	5
Sep ’25	DKK 179.00	DKK 168.60 -5.8%	15.3%	DKK 200.00	DKK 128.00	n/a	5
Aug ’25	DKK 156.50	DKK 155.40 -0.7%	11.5%	DKK 180.00	DKK 128.00	n/a	5
Jul ’25	DKK 151.10	DKK 155.40 +2.8%	11.5%	DKK 180.00	DKK 128.00	n/a	5
Jun ’25	DKK 152.60	DKK 155.00 +1.6%	11.4%	DKK 175.00	DKK 126.00	n/a	5
May ’25	DKK 131.20	DKK 132.75 +1.2%	7.6%	DKK 145.00	DKK 120.00	n/a	4
Apr ’25	DKK 124.10	DKK 125.00 +0.7%	15.0%	DKK 140.00	DKK 94.00	DKK 141.00	4
Mar ’25	DKK 130.40	DKK 120.75 -7.4%	16.5%	DKK 140.00	DKK 94.00	DKK 153.10	4
Feb ’25	DKK 110.70	DKK 112.00 +1.2%	10.6%	DKK 125.00	DKK 94.00	DKK 162.80	4
Jan ’25	DKK 101.20	DKK 110.75 +9.4%	9.6%	DKK 120.00	DKK 94.00	DKK 159.10	4
Dec ’24	DKK 91.75	DKK 110.75 +20.7%	9.6%	DKK 120.00	DKK 94.00	DKK 162.00	4
Nov ’24	DKK 76.45	DKK 117.80 +54.1%	21.3%	DKK 160.00	DKK 89.00	DKK 163.60	5
Oct ’24	DKK 79.45	DKK 112.80 +42.0%	25.2%	DKK 160.00	DKK 85.00	DKK 171.10	5
Sep ’24	DKK 83.10	DKK 116.40 +40.1%	22.5%	DKK 160.00	DKK 85.00	DKK 179.00	5
Aug ’24	DKK 74.15	DKK 128.20 +72.9%	23.6%	DKK 169.00	DKK 95.00	DKK 156.50	5
Jul ’24	DKK 74.45	DKK 128.20 +72.2%	23.6%	DKK 169.00	DKK 95.00	DKK 151.10	5
Jun ’24	DKK 82.15	DKK 124.20 +51.2%	27.0%	DKK 169.00	DKK 90.00	DKK 152.60	5
May ’24	DKK 86.50	DKK 129.20 +49.4%	22.6%	DKK 169.00	DKK 100.00	DKK 131.20	5
Apr ’24	DKK 106.10	DKK 141.20 +33.1%	15.6%	DKK 169.00	DKK 107.00	DKK 124.10	5

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

DKK 181.25

Fair Value

20.5% undervalued

Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/22 18:18
End of Day Share Price	2025/04/22 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALK-Abelló A/S is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Alexandru Cogut	Bryan Garnier & Co
Jesper Ilsoe	Carnegie Investment Bank AB